HSP90AA1 and childhood malignant neoplasm: However, DLTs associated with achieving effective depletion of HSP90, combined with the complexity of attaining therapeutic dosing of drug combinations, may limit the use of HSP90 inhibition therapies in childhood cancers like neuroblastoma.